

**Remarks**

Applicants have received a Notice of Drawing Inconsistency with Specification, asserting that Figures 1C and 1D are contained in the Drawings in the specification but are not listed in the Brief Description of the Drawings in the specification. This notice was prompted by a misunderstanding of the terminology used in the description of Figure 1, as originally filed. That description stated:

Figure 1 shows the (A) nucleic acid sequence designated SEQ ID NO: 1 and (B) the deduced amino acid sequence of the butyrylcholinesterase variant designated SEQ ID NO: 2.

This description was mistakenly understood to mean that Figure 1A is the nucleic acid sequence and the Figure 1B is the deduced amino acid sequence, leaving 1C and 1D not described. In fact, Figure 1, cumulatively, comprises both the nucleic acid sequence and the amino acid sequence. This sequence contains 574 amino acids, and thus extends onto four pages. Figures 1A, 1B, 1C, and 1D merely refer to the four pages of Figure 1.

To resolve any confusion, the specification is amended by removing the (A) and (B) designations from the description, and Figure 1, in total, is referred to as FIG. 1A-1D. This clarification of the description adds no new matter to the specification.

Respectfully submitted,

*Paula K. Davis*

Paula K. Davis  
Attorney for Applicants  
Registration No. 47,517  
Phone: 317-433-3422

Eli Lilly and Company  
Patent Division/PKD  
P.O. Box 6288  
Indianapolis, Indiana 46206-6288

13-April-2006